Concert Pharma (CNCE) Tops Q2 EPS by 3c
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of ($0.60), $0.03 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $71 thousand versus the consensus estimate of $30 thousand.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agree Realty (ADC) Tops Q3 FFO by 4c
- Avalonbay Communities (AVB) Reports In-Line Q3 FFO
- UPDATE: Corelogic (CLGX) Tops Q3 EPS by 7c, Expects to Achieve Upper Ends of FY16 Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!